REPL - Replimune Group Inc

REPL - Replimune Group Inc

https://www.replimune.com

Sell Momentum: Bearish

Recent News

Powered by Alpha Vantage

Contact The Gross Law Firm by September 22, 2025 Deadline to Join Class Action Against Replimune Group, Inc. ( REPL ) - Replimune Group ( NASDAQ:REPL )

Benzinga • 0 minutes ago • score: 0.19

NEW YORK, Sept. 15, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. REPL. Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Replimune Group ( NASDAQ:REPL )

Benzinga • 3 days ago • score: 0.24

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options

Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL - Replimune Group ( NASDAQ:REPL )

Benzinga • 3 days, 19 hours ago • score: -0.05

NEW YORK, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ( "Replimune Group, Inc." or the "Company" ) REPL of a class action securities lawsuit.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL - Replimune Group ( NASDAQ:REPL )

Benzinga • 4 days, 21 hours ago • score: 0.22

NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ( "Replimune" or the "Company" ) REPL. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ( or 888.4-POMLAW ...

REPL 2-WEEK DEADLINE ALERT: Replimune ( REPL ) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - Replimune Group ( NASDAQ:REPL )

Benzinga • 6 days, 21 hours ago • score: -0.04

SAN FRANCISCO, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Replimune Group Inc. REPL is under fire from investors following a dramatic regulatory setback that sent its stock into freefall.

Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL - Replimune Group ( NASDAQ:REPL )

Benzinga • 1 week ago • score: 0.24

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options

Replimune Group, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion. - Replimune Group ( NASDAQ:REPL )

Benzinga • 1 week, 2 days ago • score: -0.17

Investors can contact the law firm at no cost to learn more about recovering their losses

Replimune ( REPL ) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman - Replimune Group ( NASDAQ:REPL )

Benzinga • 1 week, 2 days ago • score: -0.04

SAN FRANCISCO, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Replimune Group Inc. REPL is under fire from investors following a dramatic regulatory setback that sent its stock into freefall.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.

52W High

$17.00

52W Low

$2.68

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.51

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.24

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.47

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.00%

Institutions (25–75% balanced)

104.95%

Shares Outstanding

78,056,000

Float

49,983,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-3.24

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.73%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0927

Previous

-0.0824

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025